drugset / Trial / NCT01362517

Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

NCT01362517

Phase 3 Completed 131 enrolled Crucell Holland BV
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study was to evaluate the immunogenicity and safety of the Quinvaxem vaccine (a liquid combination vaccine against diphtheria, tetanus, B. pertussis, hepatitis B and H. influenzae Type B). Healthy Vietnamese infants received three doses of vaccine at 2, 3 and 4 months of age according to the local Expanded Programme on Immunisation (EPI) schedule

Timeline

Start
2010-04
Primary completion
2010-07
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Quinvaxem Vaccine 0.5 ml